Witnessing the stock’s movement on the chart, on February 09, 2021, Neos Therapeutics Inc. (NASDAQ: NEOS) set off with pace as it heaved 9.08% to $1.06. During the day, the stock rose to $1.12 and sunk to $1.02 before settling in for the price of $0.97 at the close. Taking a more long-term approach, NEOS posted a 52-week range of $0.45-$1.84.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 143.30%. Meanwhile, its Annual Earning per share during the time was 28.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 78.80%. This publicly-traded company’s shares outstanding now amounts to $49.76 million, simultaneously with a float of $49.22 million. The organization now has a market capitalization sitting at $51.34 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7329, while the 200-day Moving Average is $0.6978.
It is imperative to bring your focus towards the efficiency factor of the conglomerate that has a total of 213 employees. It has generated 303,516 per worker during the last fiscal year. Meanwhile, its income per employee was -79,352. The stock had 2.38 Receivables turnover and 0.64 Total Asset turnover. For the Profitability, stocks gross margin was +61.14, operating margin was -16.11 and Pretax Margin of -26.13.
Neos Therapeutics Inc. (NEOS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – Specialty & Generic industry. Neos Therapeutics Inc.’s current insider ownership accounts for 1.50%, in contrast to 33.40% institutional ownership.
Neos Therapeutics Inc. (NEOS) Earnings and Revenue Records
As on 9/29/2020, Multinational firm has announced its last quarter scores, in which it reported -$0.1 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.05) by -$0.05. This company achieved a net margin of -26.14 while generating a return on equity of -1,971.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Neos Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 78.80% and is forecasted to reach -0.08 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 31.70% through the next 5 years, which can be compared against the 28.10% growth it accomplished over the previous five years trading on the market.
Neos Therapeutics Inc. (NASDAQ: NEOS) Trading Performance Indicators
Let’s observe the current performance indicators for Neos Therapeutics Inc. (NEOS). It’s Quick Ratio in the last reported quarter now stands at 0.50. The Stock has managed to achieve an average true range (ATR) of 0.08. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.90.
In the same vein, NEOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.44, a figure that is expected to reach 0.00 in the next quarter, and analysts are predicting that it will be -0.08 at the market close of one year from today.
Technical Analysis of Neos Therapeutics Inc. (NEOS)
Going through the that latest performance of [Neos Therapeutics Inc., NEOS]. Its last 5-days volume of 5.04 million was inferior to the volume of 5.15 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 72.87% While, its Average True Range was 0.0891.
Raw Stochastic average of Neos Therapeutics Inc. (NEOS) in the period of the previous 100 days is set at 81.33%, which indicates a major fall in contrast to 82.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 91.56% that was lower than 132.93% volatility it exhibited in the past 100-days period.